Humacyte Inc
HUMA2.272USD
-0.008-0.37%
交易中 （美東）報價延遲15分鐘
352.37M總市值
虧損本益比TTM
關於 Humacyte Inc 公司
Humacyte, Inc. 致力於開發和製造現成的、可普遍植入的生物工程人體組織。該公司致力於開發一系列直徑和長度各異的人體無細胞血管 (HAV)。HAV 產品最初將瞄準血管修復、重建和替換市場，包括血管創傷；血液透析的房室 (AV) 通路；外周動脈疾病 (PAD)；以及冠狀動脈搭橋術 (CABG)。該公司開發了一種用於製造人體組織的新範例，旨在模仿人體生理學的關鍵方面。該公司還致力於開發用於兒科心臟手術和細胞療法的 HAV，包括用於治療 1 型糖尿病的胰島細胞移植。該公司的科學技術平臺使用來自工作細胞庫的原代人主動脈血管細胞，這些細胞是從供體組織中分離並冷凍保存的。
公司簡介
公司代碼HUMA
公司名稱Humacyte Inc
上市日期Sep 22, 2020
CEODr. Laura E. Niklason, M.D., Ph.D
員工數量218
證券類型Ordinary Share
年結日Sep 22
公司地址2525 East North Carolina Highway 54
城市DURHAM
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編27713
電話19193139633
網址https://humacyte.com/
公司代碼HUMA
上市日期Sep 22, 2020
CEODr. Laura E. Niklason, M.D., Ph.D
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Laura E. Niklason, M.D., Ph.D
Dr. Laura E. Niklason, M.D., Ph.D
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.39M
--
Mr. Michael T. Constantino
Mr. Michael T. Constantino
Independent Director
Independent Director
32.95K
+94.40%
Dr. Shamik J. Parikh, M.D.
Dr. Shamik J. Parikh, M.D.
Chief Medical Officer
Chief Medical Officer
7.50K
--
Mr. Dale A. Sander
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
--
--
Mr. Max Wallace, J.D.
Mr. Max Wallace, J.D.
Independent Director
Independent Director
--
--
Gen. C. Bruce Green
Gen. C. Bruce Green
Independent Director
Independent Director
--
--
Dr. Susan Windham-Bannister, Ph.D.
Dr. Susan Windham-Bannister, Ph.D.
Independent Director
Independent Director
--
--
Dr. John P Bamforth, Ph.D.
Dr. John P Bamforth, Ph.D.
Independent Director
Independent Director
--
--
Mr. William (B.J.) Scheessele
Mr. William (B.J.) Scheessele
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Todd M. Pope
Mr. Todd M. Pope
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Laura E. Niklason, M.D., Ph.D
Dr. Laura E. Niklason, M.D., Ph.D
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.39M
--
Mr. Michael T. Constantino
Mr. Michael T. Constantino
Independent Director
Independent Director
32.95K
+94.40%
Dr. Shamik J. Parikh, M.D.
Dr. Shamik J. Parikh, M.D.
Chief Medical Officer
Chief Medical Officer
7.50K
--
Mr. Dale A. Sander
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
--
--
Mr. Max Wallace, J.D.
Mr. Max Wallace, J.D.
Independent Director
Independent Director
--
--
Gen. C. Bruce Green
Gen. C. Bruce Green
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024Q3
FY2022Q2
FY2022Q1
暫無數據
地區USD
名稱
營收
佔比
United States
517.00K
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fresenius SE & Co KGaA
11.81%
Yushvaev (Gavril Abramovich)
5.76%
BlackRock Institutional Trust Company, N.A.
4.86%
The Vanguard Group, Inc.
4.24%
State Street Global Advisors (US)
2.75%
Other
70.58%
持股股東
持股股東
佔比
Fresenius SE & Co KGaA
11.81%
Yushvaev (Gavril Abramovich)
5.76%
BlackRock Institutional Trust Company, N.A.
4.86%
The Vanguard Group, Inc.
4.24%
State Street Global Advisors (US)
2.75%
Other
70.58%
股東類型
持股股東
佔比
Investment Advisor
17.97%
Corporation
13.25%
Hedge Fund
8.61%
Investment Advisor/Hedge Fund
7.31%
Individual Investor
6.93%
Research Firm
2.78%
Venture Capital
2.17%
Bank and Trust
1.08%
Pension Fund
0.26%
Other
39.63%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
347
93.77M
60.45%
+11.76M
2025Q1
346
95.39M
64.76%
+11.80M
2024Q4
319
75.99M
61.96%
-3.94M
2024Q3
283
71.70M
59.72%
-5.88M
2024Q2
264
68.34M
57.06%
+3.14M
2024Q1
231
61.49M
51.37%
+1.67M
2023Q4
225
55.97M
54.06%
-5.15M
2023Q3
227
54.57M
52.73%
-6.28M
2023Q2
223
56.13M
54.24%
-11.76M
2023Q1
219
61.42M
59.44%
-8.48M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fresenius SE & Co KGaA
18.31M
11.81%
--
--
May 13, 2025
Yushvaev (Gavril Abramovich)
8.94M
5.76%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.54M
4.86%
+87.54K
+1.18%
Mar 31, 2025
The Vanguard Group, Inc.
6.57M
4.24%
+990.86K
+17.74%
Mar 31, 2025
State Street Global Advisors (US)
4.27M
2.75%
-344.53K
-7.47%
Mar 31, 2025
Heights Capital Management, Inc.
4.03M
2.59%
+4.03M
--
Mar 31, 2025
Woodline Partners LP
3.95M
2.55%
+1.10M
+38.65%
Mar 31, 2025
RA Capital Management, LP
3.31M
2.14%
+3.31M
--
Mar 31, 2025
Citadel Advisors LLC
2.91M
1.88%
+2.74M
+1598.28%
Mar 31, 2025
Ayabudge LLC
2.24M
1.44%
+510.16K
+29.47%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Clough Select Equity ETF
1.88%
Hypatia Women CEO ETF
0.15%
SPDR S&P Biotech ETF
0.1%
iShares Micro-Cap ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
查看更多
Clough Select Equity ETF
佔比1.88%
Hypatia Women CEO ETF
佔比0.15%
SPDR S&P Biotech ETF
佔比0.1%
iShares Micro-Cap ETF
佔比0.06%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
